S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:IMAB

I-Mab (IMAB) Stock Price, News & Analysis

$1.87
+0.03 (+1.63%)
(As of 03/27/2024 ET)
Today's Range
$1.79
$1.88
50-Day Range
$1.54
$2.01
52-Week Range
$1.16
$3.88
Volume
486,976 shs
Average Volume
535,326 shs
Market Capitalization
$150.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

I-Mab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
555.1% Upside
$12.25 Price Target
Short Interest
Healthy
1.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of I-Mab in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

Medical Sector

430th out of 939 stocks

Pharmaceutical Preparations Industry

203rd out of 422 stocks

IMAB stock logo

About I-Mab Stock (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Stock Price History

IMAB Stock News Headlines

I-Mab's (IMAB) "Buy" Rating Reaffirmed at HC Wainwright
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
I-Mab (NASDAQ:IMAB) PT Lowered to $6.00
Short Interest in I-Mab (NASDAQ:IMAB) Drops By 5.3%
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
I-MAB Stock (NASDAQ:IMAB), Short Interest Report
I-Mab to Divest Chinese Unit for Up to $80M
I-Mab (IMAB) interactive stock chart – Yahoo Finance
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
Ray Dalio on Potential US China War and Rise of China
Expert Ratings for I-MAB
See More Headlines
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$25.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+555.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.89 million
Book Value
$2.93 per share

Miscellaneous

Free Float
62,867,000
Market Cap
$150.91 million
Optionable
Optionable
Beta
1.10
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 60)
    CEO & Director
  • Dr. Jerry Wang
    Co-Founder & Chief Scientific Officer
  • Mr. Skelton Joseph
    Chief Financial Officer
  • Mr. Tianyi Zhang
    Vice President of Investor Relations
  • Mr. Cheng Li (Age 40)
    Chief Legal Officer
  • Ms. Gigi Qi Feng (Age 43)
    Chief Communications Officer
  • Dr. Weiming Tang Ph.D. (Age 58)
    Executive VP of Global Business Development & Chief Business Officer
  • Dr. Fernando J. Salle´s Ph.D.
    Senior VP and Head of U.S. & EU Business Development
  • Claire Xu
    Head of US site
  • Dr. John Hayslip M.D. (Age 47)
    Chief Medical Officer

IMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell I-Mab stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings
or view top-rated stocks.

What is I-Mab's stock price target for 2024?

4 analysts have issued 1-year target prices for I-Mab's shares. Their IMAB share price targets range from $6.00 to $25.00. On average, they expect the company's share price to reach $12.25 in the next year. This suggests a possible upside of 555.1% from the stock's current price.
View analysts price targets for IMAB
or view top-rated stocks among Wall Street analysts.

How have IMAB shares performed in 2024?

I-Mab's stock was trading at $1.90 on January 1st, 2024. Since then, IMAB shares have decreased by 1.6% and is now trading at $1.87.
View the best growth stocks for 2024 here
.

When is I-Mab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our IMAB earnings forecast
.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

When did I-Mab IPO?

I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

Who are I-Mab's major shareholders?

I-Mab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.65%), Schroder Investment Management Group (0.38%), Barclays PLC (0.21%), abrdn plc (0.20%), Goldman Sachs Group Inc. (0.18%) and Goldman Sachs Group Inc. (0.18%).

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners